Parabilis Medicines, Inc. (PBLS): who owns it and who trades it
As of Nov 12, 2026, PBLS insiders reported 14 purchases worth $441M in the last 12 months. The largest buyer was RA Capital Nexus Fund III, L.P. (Director), with $424M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Parabilis Medicines
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PBLS
79 funds and institutions reported PBLS shares worth $2.7B at the end of Q2 2026. The largest holder is Ra Capital Management, L.P. with $792M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 28.93M | – | $792M | – |
| FMR LLC (Fidelity) | 10.29M | – | $282M | – |
| ARCH Venture Management, LLC | 6.41M | – | $176M | – |
| VenBio Partners LLC | 5.27M | – | $144M | – |
| Alphabet Inc. | 4.92M | – | $135M | – |
| Nextech Invest Ltd. | 4.66M | – | $128M | – |
| Cormorant Asset Management, LP | 4.62M | – | $126M | – |
| Regeneron Pharmaceuticals, Inc. | 4.17M | – | $114M | – |
| Siren, L.L.C. | 2.99M | – | $81.9M | – |
| Farallon Capital Management, L.l.c. | 2.37M | – | $64.8M | – |
| Jupiter Topco LLC | 2.30M | – | $62.7M | – |
| Frazier Life Sciences Management, L.P. | 1.92M | – | $52.6M | – |
| Deerfield Management Company, L.P. | 1.88M | – | $51.5M | – |
| General Catalyst Group Management, LLC | 1.60M | – | $43.8M | – |
| General Atlantic, L.P. | 1.54M | – | $42.1M | – |
| Soleus Capital Management, L.P. | 1.47M | – | $40.1M | – |
| Vanguard Portfolio Management LLC | 1.30M | – | $35.6M | – |
| Vanguard Capital Management LLC | 1.16M | – | $31.7M | – |
| JPMorgan Chase & Co | 1.04M | – | $30.4M | – |
| Foresite Capital Management VI LLC | 999,044 | – | $27.3M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, PBLS insiders reported $441M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 47,250 | $29.77 | $1.4M | Form 4 |
| Jul 21, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 21,696 | $27.96 | $607K | Form 4 |
| Jul 21, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 6,504 | $29.17 | $190K | Form 4 |
| Jul 21, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 37,723 | $30.00 | $1.1M | Form 4 |
| Jul 20, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 32,987 | $27.72 | $914K | Form 4 |
| Jul 20, 2026 | Ra Capital Management, L.P. +4 | Director | Purchase | 98,433 | $27.13 | $2.7M | Form 4 |
| Jun 15, 2026 | Alan Sebulsky | Director | Purchase | 4,065 | $27.10 | $110K | Form 4 |
| Jun 15, 2026 | Alan Sebulsky | Director | Purchase | 5,000 | $26.00 | $130K | Form 4 |
| Jun 12, 2026 | Alan Sebulsky | Director | Purchase | 8,435 | $27.67 | $233K | Form 4 |
| Jun 11, 2026 | Soleus Capital Group, LLC +8 | 10% owner | Purchase | 125,000 | $20.00 | $2.5M | Form 4 |
| Jun 11, 2026 | Soleus Capital Group, LLC +8 | 10% owner | Purchase | 375,000 | $20.00 | $7.5M | Form 4 |
| Jun 11, 2026 | RA Capital Nexus Fund III, L.P. +4 | Director | Purchase | 19.73M | $20.00 | $395M | Form 4 |
| Jun 11, 2026 | RA Capital Nexus Fund III, L.P. +4 | Director | Purchase | 1.46M | $20.00 | $29.2M | Form 4 |
| Jun 11, 2026 | Alan Sebulsky | Director | Purchase | 12,500 | $20.00 | $250K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| RA Capital Nexus Fund III, L.P. | Director | $424M | – | Jun 11, 2026 |
| Soleus Capital Group, LLC | 10% owner | $10M | – | Jun 11, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | $6.9M | – | Jul 22, 2026 |
| Alan Sebulsky | Director | $724K | – | Jun 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PBLS short interest
11.05M PBLS shares are sold short. Over the last 10 reports the number of shares short went up 890%.
As of Oct 30, 2026, 11.05M PBLS shares were sold short, up 19.5% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 8.3 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.05M | – | +19% | 1.33M | 8.3 |
| Oct 15, 2026 | 9.25M | – | +12% | 974,200 | 9.5 |
| Sep 30, 2026 | 8.26M | – | +36% | 1.71M | 4.8 |
| Sep 15, 2026 | 6.09M | – | +10% | 459,707 | 13.2 |
| Aug 31, 2026 | 5.52M | – | +5% | 388,564 | 14.2 |
| Aug 14, 2026 | 5.26M | – | +3% | 334,084 | 15.7 |
| Jul 31, 2026 | 5.12M | – | +29% | 399,225 | 12.8 |
| Jul 15, 2026 | 3.95M | – | +43% | 476,686 | 8.3 |
| Jun 30, 2026 | 2.77M | – | +148% | 1.07M | 2.6 |
| Jun 15, 2026 | 1.12M | – | – | 838,555 | 1.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Parabilis Medicines company events
Parabilis Medicines filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AgreementParabilis Medicines, Inc. and LS 400/500 CDP, LLC entered into a Third Amendment of Lease, which amends certain provisions of that certain Lease Agreement, by and between the Company and 400 Discovery Park, LLC, dated as of April 22, 2019, as amended, regarding the Company’s corporate headquarters… Filing
- Sep 15, 2026AnnouncementShared information with investors. Filing
- Sep 2, 2026LeadershipParabilis Medicines, Inc. and Fawzi Benzaghou, M.D., the Company’s Chief Medical Officer, mutually agreed that Dr. Benzaghou would transition from the Company effective as of September 30, 2026. Filing
- Aug 25, 2026LeadershipThe Board of Directors of Parabilis Medicines, Inc. increased the number of directors of the Company to nine (9) and appointed Craig Tendler as a director of the Company to fill the newly created vacancy. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 11, 2026AgreementParabilis Medicines, Inc. entered into a Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc., for the purchase of an aggregate of 4,166,666 shares of its voting common stock, par value $0.0001, at a per share price equal to 90% of the initial public offering price of $20.00 per share… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold PBLS
1 of the 50 well-known investors we track reported holding PBLS in their latest 13F filing. The largest position is Jim Simons's, worth $429K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 13,300 | $429K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Parabilis Medicines, Inc. (PBLS) stock
Who owns the most PBLS stock?
The largest reported owner of Parabilis Medicines, Inc. (PBLS) is Ra Capital Management, L.P.. In total, 79 funds and institutions reported holding PBLS at the end of Q2 2026. See the largest owners.
Are PBLS insiders buying or selling?
In the last 12 months, PBLS insiders reported 14 open-market purchases worth $441M and no sales. The latest trade was on Jul 22, 2026. See every trade.
What is the short interest in PBLS?
As of Oct 30, 2026, 11.05M PBLS shares were sold short, up 19.5% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.
Which famous investors hold PBLS?
1 of the 50 well-known investors we track reported PBLS in their latest 13F filing, including Jim Simons. The largest position is worth $429K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.